Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Syndax Pharmaceuticals Inc (SNDX) is now available.
Syndax Pharmaceuticals, Inc. has appointed Steven Closter as the new Chief Commercial Officer following the resignation of Steve Sabus for personal reasons. Closter, an experienced professional with a history at Sunovion Pharmaceuticals and Forest Laboratories, brings significant industry expertise to his new role. With an impressive academic background from Cornell University and NYU Stern School of Business, Closter’s employment package includes a competitive salary, bonus incentives, stock options, and performance-related stock units, alongside a severance agreement that offers substantial benefits in case of termination under specific conditions. His appointment is seen as a strategic move to bolster the company’s commercial leadership in the competitive pharmaceutical market.
For an in-depth examination of SNDX stock, go to TipRanks’ Stock Analysis page.